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Background: Concurrent chemoradiation is the accepted standard of 
care for most patients with unresectable stage III A/B non-small cell 
lung cancer (NSCLC) but no standard chemotherapy regimen or sched-
ule has yet been established. Cisplatin, combined with a third genera-
tion agent, provides the greatest activity in advanced NSCLC, but to 
date, no third generation agent has been shown to be tolerable at full 
dose in combination with radiotherapy (RT) and cisplatin. Pemetrexed/
cisplatin (PemC) has shown promising activity in the advanced disease 
setting and full dose pemetrexed combined with RT or RT/carboplatin 
has been shown to be safe. 
Methods: From December 15, 2005 to December 19, 2006, 10 patients 
with unresectable stage IIIA/B NSCLC were entered on three dose 
levels of a phase I trial evaluating PemC combined with 61-66 Gy RT 
(date of last follow up February 1, 2007). Eligible patients had < 5% 
weight loss, ECOG PS 0/1, no malignant effusions, FEV1 >1.3 l and 
adequate organ function. Patients received two q21 day cycles of PemC 
(Pem 300, 400 or 500 mg/m2 - day 1, C 25 mg/m2 days 1-3) concurrent 
with RT (61 - 66 Gy over 6 to 6.5 weeks) followed by two adjuvant 
q21 day cycles (Pem 500 mg/m2 - day 1, C 75 mg/m2 - day 1). All 
patients received dexamethasone premedication and B12/folate vitamin 
supplementation.
Results: Ten patients were accrued (3 at dose levels 1 and 2, 4 at 
dose level 3). Demographics: median age - 63 years [range 46-69]; 
stage IIIA/B - 4/6; PS 0/1 - 2/8; median radiation dose - 65 Gy [range 
60.5-66]. One patient had dose reduction of cisplatin for cycles 3 and 
4 due to elevated creatinine levels, two patients received only cycles 
one and two (one due to patient refusal despite only grade 2 toxicity 
having been observed; one in a patient with pre-existing metal allergies 
who developed progressive cisplatin allergy). Two patients developed 
grade 4 neutropenia. No grade 3 neutropenia or febrile neutropenia 
was observed. One patient on dose level 3 required hospital admission 
for grade 3 esophagitis but was able to complete all planned RT and 
concurrent chemotherapy. Other grade 3 toxicities were uncommon: 
hypertension (2); diarrhea (1); anemia (1); hyperglycemia (1); hypo-
phosphatemia (1); thrombocytopenia (1). Partial response (RECIST) 
has been observed in 7/8 (88%) evaluable patients after independent 
review with no local progression to date (median f/u 5.3 months). All 
patients remain alive. One pt has developed distant relapse >12 months 
after commencing treatment.
Conclusion: Full dose PemC and full dose concurrent RT is well toler-
ated and preliminary efﬁcacy appears promising. The study is ongoing 
and has been amended to add a fourth dose level increasing the dose 
intensity of cisplatin during RT to 20 mg/m2 daily x 5. A phase II study 
is planned. 
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Background: To evaluate the treatment results and toxicities for lung 
cancer patients treated with trimodality therapy including preopera-
tive concurrent chemotherapy (CT) with high dose radiotherapy (RT) 
(>60Gy). 
Methods: Patients diagnosed with lung cancer between 8/04 and 9/06 
and treated with concurrent CT and high dose RT preoperatively at the 
DFCI/BWH were reviewed retrospectively with IRB approval. Compli-
cations and follow up data were recorded. Survival was calculated from 
the date of diagnosis using the Kaplan-Meier method.
Results: 16 patients were evaluated. The median age was 58 (40-76). 
Fifteen had NSCLC patients were stage III (8 stage IIIA, 6 stage IIIB), 
1 was stage II, one patient had limited stage SCLC with residual dis-
ease after chemoradiotherapy. All of the patients completed induction 
chemoradiotherapy (CRT). CT consisted of weekly carboplatin and 
paclitaxel for 5 patients (31%) or cisplatin and etoposide q3 wks for 
11 patients (69%). Median RT dose was 68 Gy (range: 60-70 Gy). The 
patients had their surgery at a median of 6.5 weeks (4-16 weeks) after 
the completion of RT. Pneumonectomy was performed in 2 patients, 
lobectomy in 10 patients, bilobectomy in 2 patients, lingular resection 
in 1 patient and wedge resection in 1 patient. Two patients had pCR. 
Interestingly, 12/16 patients had residual disease at the primary site 
at the time of resection. In addition, one patient was found to have 
metastatic satellite nodule in a different lobe, which was surgically 
removed. Nodal downstaging was present in 12 (75%) of the patients. 
Two patients had postop empyema and 3 of them had ipsilateral vocal 
cord paralysis. One of the patients who had empyema had a prolonged 
hospitalization because of respiratory failure. There were two cases of 
Gr 3 or greater esophagitis after CRT, one of them requiring dilation. 
Five of the patients received consolidation chemotherapy with different 
CT regimens for 2-3 cycles. Median follow up was 12.5 months (6-
30). There were 2 local recurrences; both of them were 6 months after 
surgery. 1 and 2 year local recurrence free survival rate is 90 and 77% 
respectively. Three patients had distant relapse where 2 of them were 
local relapsed patients. One and 2 year distant disease free survival rate 
is 83 and 70% respectively. Overall survival is 100% for 1 and 2 years. 
Conclusion: Preoperative high dose RT with concurrent CT is a fea-
sible approach in inoperable lung cancer with acceptable complication 
and excellent survival rates when done with experienced multidisci-
plinary team. 
